CENI, COSTANZA
CENI, COSTANZA
Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino (NEUROFARBA)
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain
2019 Falsini M.; Catarzi D.; Varano F.; Ceni C.; Dal Ben D.; Marucci G.; Buccioni M.; Volpini R.; Di Cesare Mannelli L.; Lucarini E.; Ghelardini C.; Bartolucci G.; Menicatti M.; Colotta V.
Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents
2020 Ceni C.; Catarzi D.; Varano F.; Ben D.D.; Marucci G.; Buccioni M.; Volpini R.; Angeli A.; Nocentini A.; Gratteri P.; Supuran C.T.; Colotta V.
Hybrid lipid-AuNP clusters as highly efficient SERS substrates for biomedical applications
2024 Jacopo Cardellini, Caterina Dallari, Ilaria De Santis, Lorenzo Riccio, Costanza Ceni, Amelia Morrone, Martino Calamai, Francesco Saverio Pavone, Caterina Credi, Costanza Montis, Debora Berti
Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction
2024 Costanza Ceni, Francesca Clemente, Francesca Mangiavacchi, Camilla Matassini, Rodolfo Tonin, Anna Caciotti, Federica Feo, Domenico Coviello, Amelia Morrone, Francesca Cardona, Martino Calamai
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists
2020 Falsini M.; Ceni C.; Catarzi D.; Varano F.; Dal Ben D.; Marucci G.; Buccioni M.; Marti Navia A.; Volpini R.; Colotta V.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Antioxidant-Conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain | 2019 | Falsini M.; Catarzi D.; Varano F.; Ceni C.; Dal Ben D.; Marucci G.; Buccioni M.; Volpini R.; Di Cesare Mannelli L.; Lucarini E.; Ghelardini C.; Bartolucci G.; Menicatti M.; Colotta V. | |
| Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents | 2020 | Ceni C.; Catarzi D.; Varano F.; Ben D.D.; Marucci G.; Buccioni M.; Volpini R.; Angeli A.; Nocentini A.; Gratteri P.; Supuran C.T.; Colotta V. | |
| Hybrid lipid-AuNP clusters as highly efficient SERS substrates for biomedical applications | 2024 | Jacopo Cardellini, Caterina Dallari, Ilaria De Santis, Lorenzo Riccio, Costanza Ceni, Amelia Morrone, Martino Calamai, Francesco Saverio Pavone, Caterina Credi, Costanza Montis, Debora Berti | |
| Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction | 2024 | Costanza Ceni, Francesca Clemente, Francesca Mangiavacchi, Camilla Matassini, Rodolfo Tonin, Anna Caciotti, Federica Feo, Domenico Coviello, Amelia Morrone, Francesca Cardona, Martino Calamai | |
| New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists | 2020 | Falsini M.; Ceni C.; Catarzi D.; Varano F.; Dal Ben D.; Marucci G.; Buccioni M.; Marti Navia A.; Volpini R.; Colotta V. |